We came across a bullish thesis on Bristol-Myers Squibb Company (BMY) on Disruptive analytics’ Substack by Magnus Ofstad. In ...

Citi raised the firm’s price target on Bristol Myers (BMY) to $65 from $60 and keeps a Neutral rating on the shares. Ahead of the Q4 earnings, ...

We recently compiled a list of the 15 Stocks to Invest in with Steady Dividends. In this article, we are going to take a look ...

We recently compiled a list of the 10 Best High-Yield Dividend Stocks To Invest In. In this article, we are going to take a ...

Amsterdam, the Netherlands, 28 January 2025 - Freya Pharma Solutions, [Freya Pharma, or the Company], a pharmaceutical ...

Like a champion boxer on the ropes, Bristol-Myers Squibb ( BMY 0.84%) finds itself in a challenging position. Specifically, the pharmaceutical giant's shares have declined by a disappointing 11.6% ...

Bristol-Myers Squibb’s dividend yield is 4.38%. During the last 12 months, it paid $2.48 per share in dividends. Don't Miss: Unlock the hidden potential of commercial real estate — This ...

(Bloomberg) -- Bristol Myers Squibb Co. said its new schizophrenia ... in therapeutic areas where we have scientific expertise, commercial expertise,” he said, referencing treatments for ...

Bristol-Myers Squibb continues to demonstrate strong commercial execution through its growth portfolio. In Q3 2024, key products like melanoma treatment Opdualag and heart medication Camzyos ...

Shana Cyr is Senior Corporate Counsel and Head of IP Strategy and Policy at Bristol Myers Squibb, a global biopharmaceutical ... regulatory and commercial matters, patent litigations, and business ...